Rationale, Design, and Experiences from the Vanguard Phase of the Bariatric Surgery for the Reduction of Cardiovascular Events (BRAVE) Trial

2026/07/01 by Jorge Wong, Jorge A. Wong, D Conen +35
Medicine · #Bariatric Surgery and Outcomes #Cardiovascular Disease and Adiposity #Cardiovascular Function and Risk Factors

paper · doi:10.1016/j.ahj.2026.107544

Citations

• Proportional hazards tests and diagnostics based on weighted residuals
• Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
• Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Severe Obesity
• Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:
• After 70 Years, Metabolic Surgery Has Earned a Cardiovascular Outcome Trial
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
• Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment